Tyrosine kinase

Angion to Participate in Upcoming March Investment Conferences

Wednesday, February 24, 2021 - 5:05am

Dr. Jay Venkatesan, Angions President and CEO, will also participate in a panel focused on kidney diseases at the Cowen 41st Annual Health Care Conference.

Key Points: 
  • Dr. Jay Venkatesan, Angions President and CEO, will also participate in a panel focused on kidney diseases at the Cowen 41st Annual Health Care Conference.
  • All three virtual investor conferences will take place in March 2021.
  • Angion is also currently evaluating ANG-3070, a tyrosine kinase receptor inhibitor for the treatment of fibrotic disease, in Phase 1.
  • Additionally, Angion has preclinical programs for a rho kinase 2 (ROCK2) inhibitor and a CYP11B2 (aldosterone synthase) inhibitor.

Eisai: MHLW Grants Orphan Drug Designation in Japan to Novel FGF Receptor Selective Tyrosine Kinase Inhibitor E7090

Monday, February 22, 2021 - 6:40am

In Japan, a Phase I clinical trial of E7090 was conducted, and E7090 has been designated as the target drug for the SAKIGAKE Designation System of the MHLW for the treatment of unresectable biliary tract cancer.

Key Points: 
  • In Japan, a Phase I clinical trial of E7090 was conducted, and E7090 has been designated as the target drug for the SAKIGAKE Designation System of the MHLW for the treatment of unresectable biliary tract cancer.
  • Discovered in-house by Eisai's Tsukuba Research Laboratories, E7090 is an orally available novel tyrosine kinase inhibitor that demonstrates selective inhibitory activity against fibroblast growth factor receptors (FGFR) FGFR1, FGFR2 and FGFR3.
  • et al., "Biliary tract cancer registry in Japan from 2008 to 2013", J Hepatobiliary Pancreat Sci., 2016, 23, 149-157.
  • (6) Arai Y. et al., "Fibroblast growth factor receptor 2 tyrosine kinase fusions define a unique molecular subtype of cholangiocarcinoma", Hepatology, 2014, 59, 1427-1434.

Inhibikase Therapeutics Announces First Patients Dosed in Phase 1 Clinical Trial of IkT-148009 to Treat Parkinson’s Disease and Related Disorders

Wednesday, February 17, 2021 - 1:05pm

Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase), a clinical-stage pharmaceutical company developing therapeutics to modify the course of Parkinsons disease and related disorders, today announced dosing of the first patients in its Phase 1 clinical trial of IkT-148009, an Abelson Tyrosine Kinase, or c-Abl, inhibitor for the treatment of Parkinsons disease.

Key Points: 
  • Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase), a clinical-stage pharmaceutical company developing therapeutics to modify the course of Parkinsons disease and related disorders, today announced dosing of the first patients in its Phase 1 clinical trial of IkT-148009, an Abelson Tyrosine Kinase, or c-Abl, inhibitor for the treatment of Parkinsons disease.
  • The initiation of our Phase 1 study of IkT-148009 for the treatment of Parkinsons disease represents a significant milestone for Inhibikase.
  • C-Abl then drives biochemical pathways and processes that lead to degradation of the neurons affected in Parkinsons disease.
  • Inhibikase (Nasdaq: IKT) is a clinical-stage pharmaceutical company developing therapeutics for Parkinsons disease and related disorders.

Apollomics, Inc. and Edison Oncology Announce Licensing Agreement for Novel Protein Tyrosine Kinase Inhibitor Targeting Solid Tumors

Wednesday, February 10, 2021 - 1:10am

EO1001 is a protein tyrosine kinase inhibitor (TKI) that has demonstrated irreversible inhibition of EGFR (ErbB1), HER2 (ErbB2) and HER4 (ErbB4) as a single agent.

Key Points: 
  • EO1001 is a protein tyrosine kinase inhibitor (TKI) that has demonstrated irreversible inhibition of EGFR (ErbB1), HER2 (ErbB2) and HER4 (ErbB4) as a single agent.
  • Under the terms of the agreement, Apollomics has the exclusive rights to develop and commercialize EO1001 globally, except in China, Hong Kong and Taiwan.
  • EO1001 is a protein tyrosine kinase inhibitor (TKI) that has demonstrated irreversible inhibition of EGFR (ErbB1), HER2 (ErbB2) and HER4 (ErbB4) as a single agent.
  • Edison Oncology was founded in 2018 by experienced life science industry veterans to develop and commercialize new therapies targeting the fight against cancer.

Apollomics, Inc. and Edison Oncology Announce Licensing Agreement for Novel Protein Tyrosine Kinase Inhibitor Targeting Solid Tumors

Tuesday, February 9, 2021 - 12:10pm

EO1001 is a protein tyrosine kinase inhibitor (TKI) that has demonstrated irreversible inhibition of EGFR (ErbB1), HER2 (ErbB2) and HER4 (ErbB4) as a single agent.

Key Points: 
  • EO1001 is a protein tyrosine kinase inhibitor (TKI) that has demonstrated irreversible inhibition of EGFR (ErbB1), HER2 (ErbB2) and HER4 (ErbB4) as a single agent.
  • Under the terms of the agreement, Apollomics has the exclusive rights to develop and commercialize EO1001 globally, except in China, Hong Kong and Taiwan.
  • EO1001 is a protein tyrosine kinase inhibitor (TKI) that has demonstrated irreversible inhibition of EGFR (ErbB1), HER2 (ErbB2) and HER4 (ErbB4) as a single agent.
  • Edison Oncology was founded in 2018 by experienced life science industry veterans to develop and commercialize new therapies targeting the fight against cancer.

Global Spleen Tyrosine Kinase (SYK) Inhibitors Pipeline Insight Report 2020 Featuring Genosco, Portola Pharmaceuticals, GlaxoSmithKline, FUJIFILM, TopiVert, Takeda Oncology & Asana BioSciences - ResearchAndMarkets.com

Friday, February 5, 2021 - 12:41pm

The "Spleen Tyrosine Kinase (SYK) Inhibitors - Pipeline Insight, 2020" drug pipelines has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Spleen Tyrosine Kinase (SYK) Inhibitors - Pipeline Insight, 2020" drug pipelines has been added to ResearchAndMarkets.com's offering.
  • This "Spleen Tyrosine Kinase (SYK) Inhibitors - Pipeline Insight, 2020" report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Spleen Tyrosine Kinase (SYK) Inhibitors pipeline landscape.
  • Spleen Tyrosine Kinase (SYK) Inhibitors: Therapeutic Assessment
    This segment of the report provides insights about the different Spleen Tyrosine Kinase (SYK) Inhibitors drugs segregated based on following parameters that define the scope of the report, such as:
    There are approx.
  • The companies which have their Spleen Tyrosine Kinase (SYK) Inhibitors drug candidates in the most advanced stage, i.e.

Asana BioSciences’ Gusacitinib Granted FDA Fast-Track Designation for Moderate-to-Severe Chronic Hand Eczema

Wednesday, February 3, 2021 - 2:00pm

Asana BioSciences, a clinical stage biopharmaceutical company, announced today that the U.S. Food and Drug Administration (FDA) has granted Fast-Track designation to Asanas gusacitinib (ASN002), an investigational oral, dual inhibitor of Janus Kinase (JAK) and Spleen Tyrosine Kinase (SYK), for the treatment of moderate-to-severe Chronic Hand Eczema (CHE).

Key Points: 
  • Asana BioSciences, a clinical stage biopharmaceutical company, announced today that the U.S. Food and Drug Administration (FDA) has granted Fast-Track designation to Asanas gusacitinib (ASN002), an investigational oral, dual inhibitor of Janus Kinase (JAK) and Spleen Tyrosine Kinase (SYK), for the treatment of moderate-to-severe Chronic Hand Eczema (CHE).
  • Patients with CHE suffer greatly from this disease, which limits their ability to work and perform activities of daily living.
  • There are no approved treatments for patients suffering from CHE in the U.S. and in many other major markets.
  • We are pleased that the FDA has granted Fast-Track designation to gusacitinib.

High Cancer Prevalence and Rise in Number of Pharmacies to Boost Growth Rate of Kinase Inhibitors Market: TMR

Tuesday, January 26, 2021 - 10:30am

The growing utilization of kinase inhibitors in cancer therapies may bring immense growth prospects for the kinase inhibitors market.

Key Points: 
  • The growing utilization of kinase inhibitors in cancer therapies may bring immense growth prospects for the kinase inhibitors market.
  • Various drug discovery programs have led to effective kinase inhibitors, thus influencing the growth of the kinase inhibitors market to a great extent.
  • The utilization of tyrosine kinase inhibitors for treating a plethora of autoimmune and inflammatory skin diseases may bring expansive growth prospects for the kinase inhibitors market.
  • Gain insights into theKinase Inhibitors Market (Type: Non-receptor Tyrosine Kinase Inhibitors, Receptor Tyrosine Kinase Inhibitors, Multikinase Inhibitors, Serine/Threonine Kinase Inhibitors, Protein Kinase C Inhibitors, RHO Kinase Inhibitors, and Others; Application: Oncology, Inflammatory Diseases, and Others; and Distribution Channel: Hospital Pharmacies, Independent Pharmacies, and Online Pharmacies) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2019 - 2027 at https://www.transparencymarketresearch.com/report-toc/818
    North America's kinase inhibitors market is extrapolated to invite tremendous growth opportunities across the assessment period.

High Cancer Prevalence and Rise in Number of Pharmacies to Boost Growth Rate of Kinase Inhibitors Market: TMR

Tuesday, January 26, 2021 - 10:30am

The growing utilization of kinase inhibitors in cancer therapies may bring immense growth prospects for the kinase inhibitors market.

Key Points: 
  • The growing utilization of kinase inhibitors in cancer therapies may bring immense growth prospects for the kinase inhibitors market.
  • Various drug discovery programs have led to effective kinase inhibitors, thus influencing the growth of the kinase inhibitors market to a great extent.
  • The utilization of tyrosine kinase inhibitors for treating a plethora of autoimmune and inflammatory skin diseases may bring expansive growth prospects for the kinase inhibitors market.
  • Gain insights into theKinase Inhibitors Market (Type: Non-receptor Tyrosine Kinase Inhibitors, Receptor Tyrosine Kinase Inhibitors, Multikinase Inhibitors, Serine/Threonine Kinase Inhibitors, Protein Kinase C Inhibitors, RHO Kinase Inhibitors, and Others; Application: Oncology, Inflammatory Diseases, and Others; and Distribution Channel: Hospital Pharmacies, Independent Pharmacies, and Online Pharmacies) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2019 - 2027 at https://www.transparencymarketresearch.com/report-toc/818
    North America's kinase inhibitors market is extrapolated to invite tremendous growth opportunities across the assessment period.

Fenebrutinib (GDC-0853, RG7845): An Orally Administered Bruton's tyrosine Kinase (BTK) Inhibitor Designed to Block B Cell Proliferation - Emerging Insights and Market Forecast to 2030 - ResearchAndMarkets.com

Wednesday, December 23, 2020 - 5:29pm

"FENEBRUTINIB- Emerging Insight and Market Forecast - 2030" the report provides comprehensive insights about an investigational product for Chronic Spontaneous Urticaria in 7 Major Markets.

Key Points: 
  • "FENEBRUTINIB- Emerging Insight and Market Forecast - 2030" the report provides comprehensive insights about an investigational product for Chronic Spontaneous Urticaria in 7 Major Markets.
  • Further, it also consists of future market assessments inclusive of the market forecast, SWOT analysis, market competitors, and other emerging therapies.
  • Fenebrutinib (GDC-0853, RG7845) is an orally administered Bruton's tyrosine kinase (BTK) inhibitor designed to block B cell proliferation and the resulting excessive immune response seen in autoimmune disorders.
  • A comprehensive product overview including the product description, mechanism of action, dosage and administration, Research and Development activity.